Related Experiment Video
Updated: May 12, 2026
Novel and Innovative Hybrid Technique for Type A Aortic Dissection
Published on: March 28, 2025
Experience with early TEVAR treatment of uncomplicated type B aortic dissection
J Lin1, C Marrocco, J Galovich
1Division of Vascular Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA. linj2011@gmail.com
Insights
Thoracic endovascular aortic repair (TEVAR) shows promise for chronic type B aortic dissection, but more research is needed. Current evidence suggests TEVAR may outperform medical management in specific patient groups.
Area of Science:
- Cardiovascular Surgery
- Vascular Endovascular Therapy
- Aortic Disease Management
Background:
- Chronic type B aortic dissection is primarily managed with medical treatment and surveillance for complications.
- Thoracic endovascular aortic repair (TEVAR) is increasingly considered for specific patient subgroups.
- Existing registries and meta-analyses suggest potential benefits of TEVAR in uncomplicated cases.
Purpose of the Study:
- To review the current treatment paradigm for chronic type B aortic dissection.
- To evaluate the role and evidence supporting thoracic endovascular aortic repair (TEVAR) in this patient population.
- To discuss the evolving indications and future directions for TEVAR in aortic disease.
Main Methods:
- Review of existing literature, including registry data (European Collaborator Registry, Talent Thoracic Retrospective Registry) and meta-analyses.
- Analysis of findings from the INSTEAD trial, a randomized trial comparing TEVAR to medical management.
- Discussion of current FDA approvals and off-label use of TEVAR devices for aortic dissection.
Main Results:
- Uncomplicated type B dissection patients undergoing TEVAR showed better outcomes compared to complicated cases in registry data.
- The INSTEAD trial found no early benefit of TEVAR over medical management, though mid-term data may indicate advantages.
- Current FDA approval for TEVAR devices in the US is limited to descending thoracic aortic aneurysm and transection.
Conclusions:
- TEVAR is a developing treatment option for chronic type B aortic dissection, with ongoing research needed to establish its definitive role.
- Further randomized controlled trials are essential to potentially shift the treatment paradigm towards broader TEVAR utilization.
- The application of TEVAR is expanding into hybrid procedures and ascending aorta interventions, indicating continued innovation.
Abstract:
The current paradigm for the treatment of chronic type B aortic dissection involves primarily medical treatment. The patients are then followed for sequelae like progressive dissection or aneurysmal degeneration, selecting this subgroup for further intervention. The European Collaborator Registry, the Talent Thoracic Retrospective Registry, and several meta-analysis showed that the uncomplicated type B dissection patients who underwent thoracic endovascular aortic repair (TEVAR) outperformed their counterpart in the complicated group. The INSTEAD trial, the first randomized trial to examine whether TEVAR is better than medical management in the chronic stable dissection patients, showed no benefit early on although mid-term data might show some benefit. Clearly more randomized controlled trials are necessary to create a paradigm shift. In the United States, the FDA approved TEVAR devices are for the descending thoracic aortic aneurysm and transection only. The use of these devices for dissection is off-label or for investigation only. As future study might broaden the use of TEVAR for the chronic dissection patients, the use of TEVAR in hybrid surgery and in the ascending aorta is also broadening the indication for this technology. With two decades of innovation behind, TEVAR will continue to evolve and innovate in the years ahead.
